{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:01:12Z","timestamp":1787007672875,"version":"build-2736575974"},"reference-count":41,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/21645515.2021.1885279","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:33:00Z","timestamp":1618615980000},"page":"2298-2310","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries"],"prefix":"10.1080","volume":"17","author":[{"given":"Prashant","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashaben","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi R.","family":"Pullagurla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bird","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwadara","family":"Ogun","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan S.","family":"Kumru","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahd","family":"Hamidi","sequence":"additional","affiliation":[{"name":"Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Hoeksema","sequence":"additional","affiliation":[{"name":"Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Yallop","sequence":"additional","affiliation":[{"name":"Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Bines","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Department of Paediatrics, University of Melbourne, Parkville, Australia"},{"name":"Department of Gastroenterology and Clinical Nutrition, Royal Children\u2019s Hospital, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1013"},{"key":"e_1_3_4_3_1","unstructured":"World Health Organization. WHO recommends use of rotavirus vaccines in all national immunization programmes. [accessed 2020 Sept 23]. http:\/\/www.who.int\/immunization\/newsroom\/newsstory_rotavirus_vaccines_immunization_programmes\/en\/."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1015"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706804"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.10.007"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000236"},{"key":"e_1_3_4_8_1","unstructured":"International Vaccine Access Center (IVAC) Johns Hopkins Bloomberg School of Public Health. VIEW-hub. [accessed 2020 Sept 23]. www.view-hub.org."},{"key":"e_1_3_4_9_1","unstructured":"Centers for Disease Control and Prevention. Rotavirus Vaccination. [accessed 2020 Sept 23]. https:\/\/www.cdc.gov\/vaccines\/vpd\/rotavirus\/index.html."},{"key":"e_1_3_4_10_1","unstructured":"World Health Organization. WHO prequalified vaccines. [accessed 2020 Sept 23]. https:\/\/extranet.who.int\/gavi\/PQ_Web\/."},{"key":"e_1_3_4_11_1","unstructured":"Burke CJ Volkin DB. Rotavirus vaccine formulations. United States Patent number US 6 616 931 469 B1. 2000."},{"key":"e_1_3_4_12_1","unstructured":"Vincent VV. Live attenuated rotavirus vaccine for oral administration. United States Patent number US 8 192 747 B2. 2006."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3329\/jhpn.v26i4.1879"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.076"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/595702"},{"key":"e_1_3_4_16_1","unstructured":"Vadrevu KM Prasad SD. Rotavirus vaccine compositions and process for preparing the same. United States Patent number US 2015\/0098967 A1. 2013."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz333"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410x(93)90025-s"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60317-2"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.015"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.09.047"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780471729259.mc15c03s15"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.08.013"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2017.07.145"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.5.6.780-783.1998"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.08.013"},{"key":"e_1_3_4_27_1","unstructured":"Laerd Statistics. Pearson product-moment correlation. [accessed 2020 Sept 23]. https:\/\/statistics.laerd.com\/statistical-guides\/pearson-correlation-coefficient-statistical-guide.php."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.12.018"},{"key":"e_1_3_4_29_1","unstructured":"Pullagurla SR Kumar P Ogun O Kumru OS Hamidi A Hoeksema F Yallop C Bines JE Volkin DB Joshi SB. Modeling the long-term stability profiles of a live rotavirus (RV3-BB) vaccine candidate in various liquid formulations via extrapolations of real-time and accelerated stability data. (manuscript in preparation)."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.08.009"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","unstructured":"Hamidi A Hoeksema F Velthof P Lemckert A Gillissen G Luitjens A Bines JE Pullagurla SR Kumar P Volkin DB et al. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Submitted 2020.","DOI":"10.1016\/j.vaccine.2021.03.033"},{"key":"e_1_3_4_32_1","unstructured":"Formulation development of a stable orally delivered live human neonatal Rotavirus (RV3-BB) vaccine candidate. Vaccine technology VII. [accessed 2020 Sept 23]. http:\/\/dc.engconfintl.org\/vt_vii\/24\/."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00227-3"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1252493"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.087"},{"key":"e_1_3_4_36_1","unstructured":"U.S. National Library of medicine. A phase II dose-ranging study of oral RV3-BB rotavirus vaccine. [accessed 2020 Sept 23]. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03483116."},{"key":"e_1_3_4_37_1","unstructured":"U.S. National Library of medicine. Immunogenicity and safety of rotavirus RV3 vaccine (bio farma) in neonates. [accessed 2020 Sept 23]. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04185545"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.008"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.07.006"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-43-2-403"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.09.034"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1487499"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2021.1885279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:05:48Z","timestamp":1709287548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2021.1885279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/21645515.2021.1885279"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2021.1885279","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}